Abstract
Talaporfin sodium (TS) is a light-activated small molecule in development for the treatment of solid tumors. TS was evaluated in combination with a proprietary drug activator in a phase I/II safety and efficacy trial in patients with hepatocellular carcinoma (HCC). To our knowledge, this is the first clinical study of light-activated drug therapy in patients with HCC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
